All News
Mic drop moments in #OA research by David Walsh! Focus on the bone- subchondral bone main be the PAIN POINT. @rheumnow #ACR23 https://t.co/PxCQ68YsTx
Bella Mehta bella_mehta ( View Tweet)
Type III relapsing polychondritis has the MAGIC and VEXAS groups, with genital ulcers and haematological manifestations, 8% of RP patients have VEXAS, Ferrada M, #ACR23 @RheumNow https://t.co/FsmBK0F7ZD
Dr. Antoni Chan ( View Tweet)
Pain without inflammation might be a myth! We need to understand a lot of immune cells before saying that! Important perpheral drivers may be important to study too!
#ACR23 @RheumNow https://t.co/VaRC1WAmiJ
Bella Mehta bella_mehta ( View Tweet)
On way to #ACR23 via Denver. good news - got upgraded, bad news late flight so tight connection. Looking forward to science, meeting in person and perfect weather….and did I say shopping, zoo, parks and food! @rheumnow https://t.co/611Y2QnfjR
Janet Pope ( View Tweet)
What’s not to love 💗 about #San Diego #ACR23 convention center? @ACRheum Follow reports @RheumNow for great updates! https://t.co/6CrQ4ifnzt
Janet Pope ( View Tweet)
@maferradastrong is an inspiration.
She was driven to improve outcomes for relapsing polychondritis, the disease she lives with, & now she leads her field.
Truly the model of a patient-physician, always so much to learn from her.
#ACR23 Review Course @RheumNow @Polychondritis https://t.co/1HJSFqgWEK
David Liew drdavidliew ( View Tweet)
Relapsing polychondritis RP is a systemic condition and not just inflammation in the ears 👂 Ferrara M #ACR23 @RheumNow https://t.co/BXvyWYMYa0
Dr. Antoni Chan ( View Tweet)
Outcome scores for TTP, using the PLASMIC score to decide on treatment for TTP, Ortel T, #ACR23 @RheumNow https://t.co/Gbn7ZqkH5Y
Dr. Antoni Chan ( View Tweet)
The role of caplacizumab in the treatment of TTP, Ortel T #ACR23 @RheumNow https://t.co/VAWOlNBRuh
Dr. Antoni Chan ( View Tweet)
Subchondral bone lesions in #OA on the weight bearing regions are the source of pain - David Walsh excellent talk summarizing pain mechanisms. #ACR23 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
Recombinant ADAMTS13 therapy just @US_FDA approved - will save these patients recurrent plasma infusions (every couple of weeks for months), a big win.
https://t.co/lKdWTMp2oc
#ACR23 Review Course @RheumNow https://t.co/2NMbJvseiA
David Liew drdavidliew ( View Tweet)
Summary of recommendations for thrombotic microangiopathy (TMA), think of ADAMTS13, Ortel T, #ACR23 @RheumNow https://t.co/eSaocPSLUH
Dr. Antoni Chan ( View Tweet)
RheumNow’s expanded coverage of the #ACR23 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Bummed to miss sunny San Diego but still excited to join #ACR23 @RheumNow
Time to get some learnin' on!
Informative review on the role of systemic treatments and the rheumatologists role in ocular inflammation. https://t.co/0nFDEZHfGW
Robert B Chao, MD ( View Tweet)
Things for me to take back to the clinic in looking after JIA patients, Sadun R, #ACR23 @RheumNow https://t.co/YkiP4GZG19
Dr. Antoni Chan ( View Tweet)
Did you know about Tubulointerstitial nephritis uveitis (TINU) syndrome? Usually younger pts; uveitis may not be concurrent with the TIN. Risks: NSAID/abx, infx, genetics. Nice systematic review of this entity (link below). #boardquestion @rheumnow #ACR23 https://t.co/HDqLDHyGM6
TheDaoIndex KDAO2011 ( View Tweet)
Systemic inflammatory conditions related to scleritis #ACR23 @RheumNow https://t.co/qc6szUnOUl
Dr. Antoni Chan ( View Tweet)
Conditions diagnosed by ophthalmologists that require systemic therapy #ACR23 @RheumNow https://t.co/tPkdoH3m9c
Dr. Antoni Chan ( View Tweet)
Isolated uveitis without systemic symptoms: Sympathetic ophthalmia, Birdshot chorioretinopathy, serpiginous , pars planitis -Dr L Kopplin @rheumnow #ACR23 #ACRReview https://t.co/prBVuZSJV7
TheDaoIndex KDAO2011 ( View Tweet)
FAST trial, MMF vs MTX at the Review Course today
Overall a big win for MTX, powered for noninferiority (bc people loved MMF) but looks like MTX won the day w/10% difference in outcomes
Take home: MTX FTW per usual
@RheumNow #ACR23 #ReviewCourse https://t.co/lY1V6S7X3d
Mike Putman EBRheum ( View Tweet)